RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
October 6, 2026
· Epidarex Capital Fund IV participates in Series A alongside BioGeneration Ventures, Angelini Ventures, Kurma Partners, Vesalius Biocapital Partners, ROM-Utrecht Region, p53 Invest and Kerna